What is EDIT (EDIT) stock price today?

EDIT (EDIT) is currently trading at $2.62, down 2.24% today.

What is EDIT P/E ratio?

EDIT's P/E ratio is -1.39. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is EDIT return on equity (ROE)?

EDIT's return on equity (ROE) is -592.59%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is EDIT's market cap?

EDIT has a market capitalization of $256.50M.

NASDAQ · Biotechnology

EDIT (EDIT) Stock

$2.62 -2.24% NASDAQ: EDIT Healthcare

Valuation

Metric	Value
Price	$2.62
Market Cap	$256.50M
P/E Ratio	-1.39
P/B Ratio	9.10
P/S Ratio	6.58
EPS (TTM)	$-1.80
52-Week High	$4.54
52-Week Low	$1.66
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-592.59%
ROA	-85.56%
ROCE	-353.57%
Gross Margin	-241.46%
Operating Margin	-241.46%
Net Margin	-2.82%
Debt/Equity	16.33
Current Ratio	3.57

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$26.0M	$20.0M	$78.0M	$32.0M	$41.0M
Operating Profit	$-193.0M	$-226.0M	$-169.0M	$-251.0M	$-99.0M
Net Profit	$-193.0M	$-220.0M	$-153.0M	$-237.0M	$-160.0M
EPS	$-2.85	$-3.21	$-2.02	$-2.88	$-1.80
Op Margin	-756.1%	-1146.3%	-216.6%	-777.2%	-245.2%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$677.0M	$514.0M	$499.0M	$342.0M	$187.0M
Total Liabilities	$124.0M	$154.0M	$150.0M	$207.0M	$159.0M
Cash	$204.0M	$142.0M	$124.0M	$132.0M	$147.0M
Borrowings	$26.0M	$44.0M	$49.0M	$35.0M	$77.0M

Latest News

Why Is Editas (EDIT) Down 12.4% Since Last Earnings Report? Zacks · Jun 4, 2026 CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026? Motley Fool · May 31, 2026 Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference GlobeNewswire · May 28, 2026 Editas Medicine Prices Public Offering of Shares, Warrants MT Newswires · May 26, 2026 Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering GlobeNewswire · May 26, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-164.0M	$-177.0M	$-132.0M	$-210.0M	$-165.0M
Investing Cash Flow	$-62.0M	$110.0M	$-8.0M	$153.0M	$138.0M
Financing Cash Flow	$33.0M	$0	$1.0M	$0	$0
Net Cash Flow	$64.0M	$-62.0M	$-18.0M	$8.0M	$14.0M
Free Cash Flow	$-172.0M	$-181.0M	$-137.0M	$-219.0M	$-166.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	—
EV / EBITDA	—
FCF Yield	-55.43%
Quick Ratio	3.22
Interest Coverage	-16.50
Return 1Y	-21.10%
Return 3Y	-68.48%
Return 5Y	-92.47%

Ownership

Insiders Held0.17%

Institutions Held49.30%

Institutions Float Held49.38%

Institutional Holder	Shares	Report Date
Blackrock Inc.	9,263,312	2026-03-31
Vanguard Capital Management LLC	4,204,369	2026-03-31
Renaissance Technologies, LLC	3,972,160	2026-03-31
Vanguard Portfolio Management LLC	3,148,570	2026-03-31
Geode Capital Management, LLC	2,311,789	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ALLO	$1.95	+2.63%	-2.17	$673.05M	0.00%
AVIR	$4.75	+1.06%	-2.13	$380.13M	0.00%
CABA	$2.71	-2.17%	-2.23	$441.88M	0.00%
CAPR	$3.93	-5.76%	-50.70	$227.59M	0.00%
IMMPImmutep Limited	$0.44	+0.90%	-0.94	$64.36M	0.00%

About EDIT

EDIT is led by CEO Gilmore O'Neill, employs 246 people, headquartered in US, publicly traded since 2016.

EDIT stock trades at $2.62 with a market capitalization of $256.50M. The stock is valued at a price-to-earnings (P/E) ratio of -1.39, price-to-book of 9.10, price-to-sales of 6.58. Over the past 52 weeks the stock has ranged between $1.66 and $4.54, and currently trades 42.3% below its 52-week high.

On profitability, EDIT generates a return on equity (ROE) of -592.59%, return on capital employed of -353.57%, an operating margin of -241.46%, a net profit margin of -2.82%.

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides